Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Critères d'exclusion

1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis) 2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion). 3. Patients with ASA classification \> 3 4. Albumin \< 30 g/liter 5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease 6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression 7. BMI ≥ 40 8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery. 9. The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor. 10. Patient has been taking regular systemic/ steroid medication in the last 6 months. 11. Patients is taking antimetabolites or antiplatelet agents. 12. Patient has preexisting sphincter problems 13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis. 14. Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT) 15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data 16. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.